Fig. 2

Changes in peripheral blood mononuclear cell (PBMC) populations. Percentage of indicated cell type in patients treated with sotigalimab, cabiralizumab and nivolumab at cycle 1, day 1 (C1D1), cycle 1, day 2 (C1D2) and cycle 2, day 1 (C2D1). ns = not significant, *p < 0.05, **p < 0.01, ***p < 0.001